
VistaShares Adds to Income ETF Suite with Launch of
SAN FRANCISCO & BOSTON & NEW YORK--(BUSINESS WIRE)-- VistaShares, an innovative asset manager seeking to disrupt the status quo in thematic exposures, income investing, and more, today announced another significant addition to its ETF lineup with the launch of the VistaShares Target 15™ USA Quality Income ETF (QUSA).
'The universe of factor ETFs is massive, with over $100 billion in investor dollars across the range of available funds. But to this point, there were no ETFs that provided factor-driven exposures with an equity options overlay..." Adam Patti, VistaShares.
Share
The Fund is the first to provide investors with an equity portfolio made up of U.S. stocks exhibiting strong quality characteristics with an actively managed options overlay that aims to achieve an annual income target of 15%, distributed 1.25% monthly.
'The universe of factor ETFs is massive, with over $100 billion in investor dollars across the range of available funds. But to this point, there were no ETFs that provided factor-driven exposures with an equity options overlay. We're thrilled to be first to market with QUSA as the next addition to our Target 15™ lineup of funds,' said Adam Patti, CEO of VistaShares.
QUSA joins the VistaShares Target 15™ Berkshire Select Income ETF (OMAH) in the VistaShares family. OMAH provides investors with exposure to an equity portfolio designed to reflect a select group of the publicly disclosed investments of Berkshire Hathaway while also building in an actively managed options overlay that aims to achieve the same annual income target of 15% (distributed 1.25% monthly).
Since launching in early March of 2025, OMAH has performed as designed and has quickly grown to over $100 million in AUM.
Also like the OMAH ETF, QUSA seeks to generate income primarily through the use of options strategies involving options contracts on its Underlying Securities. These strategies are overseen by the highly experienced options trading team at Tidal Financial Group, with Jay Pestrichelli, the Chief Trading Officer at Tidal Financial Group and the portfolio manager of many other highly acclaimed Income ETFs, in the role of lead portfolio manager for the QUSA options overlay.
'With OMAH, we introduced a way for investors to unlock the income component that has long been missing from exposure to Berkshire Hathaway. Now, with QUSA, we're bringing attractive income potential to the well-established world of factor investing,' added Patti. 'A core equity exposure can now simultaneously deliver high monthly income potential. It is nothing short of a game changer when it comes to introducing greater efficiencies into the portfolio construction process.'
For more information and updates from VistaShares, please visit www.VistaShares.com and follow the firm on Linkedin @VistaShares and on X @VistaSharesETFs.
About VistaShares
At VistaShares, we strive to deliver innovative investment solutions for today's investors, helping them navigate evolving market opportunities with confidence. VistaShares ETFs are actively managed by industry and investment experts, offering two distinct strategies. Our Pure Exposure™ ETFs target technology-driven economic Supercycles™ that we believe are poised for significant growth. Additionally, our Target 15 ™ option-based income ETFs are designed to generate high monthly income while complementing a core equity portfolio.
Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the Fund, please call (844) 875-2288. Read the prospectus or summary prospectus carefully before investing.
Investing involves risk, including possible loss of principal.
The Distribution rate is the estimated payout an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward. The Distribution Rate is calculated by multiplying an ETF's Distribution per Share by twelve (12), and dividing the resulting amount by the ETF's most recent NAV. The Distribution Rate represents a single distribution from the ETF and does not represent its total return. Distributions are not guaranteed.
The Distribution rate and 30-Day SEC Yield is not indicative of future distributions, if any, on the ETFs. In particular, future distributions on any ETF may differ significantly from its Distribution Rate or 30-Day SEC Yield. You are not guaranteed a distribution under the ETFs. Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero. Accordingly, the Distribution Rate and 30-Day SEC Yield will change over time, and such change may be significant. The distribution may include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease a fund's NAV and trading price over time. As a result, an investor may suffer significant losses to their investment. These distribution rates caused by unusually favorable market conditions may not be sustainable. Such conditions may not continue to exist and there should be no expectation that this performance may be repeated in the future.
Index / Strategy Risks. The Index's holdings are derived from publicly available data, which may be delayed relative to the then current portfolio of Berkshire Hathaway. Consequently, the Fund's holdings, which are based on the Index, may not accurately reflect Berkshire Hathaway's most recent publicly-disclosed investment positions and may deviate substantially from its actual current Portfolio. The equity securities represented in the Index are subject to a range of risks, including, but not limited to, fluctuations in Market conditions, increased competition, and evolving regulatory environments, all of which could adversely affect their performance. Focused Portfolio Risk. The Fund will hold a relatively focused portfolio that may contain exposure to the securities of fewer issuers than the portfolios of other ETFs. Holding a relatively concentrated portfolio may increase the risk that the value of the Fund could go down because of the poor performance of one or a few investments. Distribution Risk. Although the Fund has an annual income target, the Fund intends to distribute income on a monthly basis. There is no assurance that the Fund will make a distribution in any given month. Derivatives Risk. Derivatives are financial instruments that derive value from the underlying reference asset or assets, such as stocks, bonds, or funds (including ETFs), interest rates or indexes. Options Contracts Risk. The use of options contracts involves investment strategies and risks different from those associated with ordinary portfolio securities transactions. The prices of options are volatile and are influenced by, among other things, actual and anticipated changes in the value of the underlying instrument, including the anticipated volatility, which are affected by fiscal and monetary policies and by national and international political, changes in the actual or implied volatility or the reference asset, the time remaining until the expiration of the option contract and economic events. Equity Market Risk. Common stocks are generally exposed to greater risk than other types of securities, such as preferred stock and debt obligations, because common stockholders generally have inferior rights to receive payment from specific issuers. The equity securities held in the Fund's portfolio may experience sudden, unpredictable drops in value or long periods of decline in value. U.S. Government and U.S. Agency Obligations Risk. The Fund may invest in securities issued by the U.S. government or its agencies or instrumentalities. U.S. Government obligations include securities issued or guaranteed as to principal and interest by the U.S. Government, its agencies or instrumentalities, such as the U.S. Treasury. New Fund Risk. The Fund is a recently organized management investment company with no operating history. As a result, prospective Investors do not have a track record or history on which to base their investment decisions. Newer Sub-Adviser Risk. VistaShares is a recently formed entity and has limited experience with managing an exchange-traded fund, which may limit the Sub-Adviser's effectiveness.
Foreside Fund Services, LLC, distributor.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
an hour ago
- Business Upturn
Biotalys Reports Progress in the Regulatory Review of EVOCA in both US and EU
By GlobeNewswire Published on June 11, 2025, 10:00 IST Ghent, BELGIUM, June 11, 2025 (GLOBE NEWSWIRE) — Press release Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, is pleased to announce progress in the regulatory approval procedures in both the United States and Europe of its first protein-based biocontrol product, EVOCA™*. In the US, Biotalys received a communication from the Environmental Protection Agency (EPA) that the company has provided responses to all the agency's requests for additional information. The EPA currently projects it will complete the scientific review of the EVOCA dossier later this summer and make a regulatory decision by September 30th, 2025. In Europe, Biotalys is pleased to confirm that both the Dutch Board for Authorisation of Plant Protection Products (CTGB) and the Dutch Institute for Health and Environment (RIVM) have now provided positive evaluations of EVOCA's regulatory dossier, paving the way for the peer review phase at the European level. In their review, both Dutch authorities have classified EVOCA's active ingredient as low risk based on the current data. This classification is important as it recognizes the active ingredient's safety profile and aligns with Biotalys' commitment to delivering sustainable, effective solutions for crop protection. No critical areas of concern were identified and therefore the Netherlands, as rapporteur Member State, proposes that the active ingredient of EVOCA can be approved in Europe, subject to the provision of certain additional data during the peer review phase. Biotalys' current assessment is that a regulatory decision in the European Union can be expected in the second half of 2026. Kevin Helash, Chief Executive Officer of Biotalys, said: 'We are pleased with the regulatory progress in both the US and EU, and look forward to a favorable outcome. An approval decision would be a major milestone for our company and a validation for our unique AGROBODY™ technology platform. This platform has the potential to develop many more protein-based biocontrol solutions for growers to fight key pests and diseases in agriculture. I am very grateful for the thorough review and guidance by the regulatory agencies, and for the hard work by our team to generate and provide the required scientific data on our innovative product.' The first biocontrol developed on Biotalys' AGROBODY™ technology platform, EVOCA helps safely control fungal diseases Botrytis (grey mold) and powdery mildew for fruit and vegetable growers looking to add effective, biodegradable solutions to their integrated pest management (IPM) initiatives to reduce chemical applications. * EVOCA™: Pending Registration. This product is not currently registered for sale or use in the European Union, the United States or elsewhere and is not being offered for sale. About Biotalys Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on For further information, please contact: Toon Musschoot, Head of IR & CommunicationT: +32 (0)9 274 54 00 E: [email protected] Important Notice Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website. This announcement contains statements which are 'forward-looking statements' or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
6 hours ago
- Yahoo
Brooks Running CEO reveals business advice from Warren Buffett's Berkshire Hathaway
Brooks Running CEO Dan Sheridan shared a leadership tip with Fortune that he learned from Warren Buffett's Berkshire Hathaway. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data